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The antiphospholipid syndrome (aPS)is a systemic autoimmune disordercharacterized by persistent moderate
to high titers of antiphospholipid antibodies
(aPL), with venous or arterial thrombosis,
pregnancy morbidity and thrombocytope-
nia.1 It is widely accepted that the pathogen-
esis of this disorder is due to the contribu-
tion of aPL, although the precise mecha-
nisms are unknown. aPL are a family of het-
erogeneous autoantibodies directed against
phospholipid-binding proteins and include
lupus anticoagulants (LA) and anticardiolipin
antibodies (aCL).2,3 The two most common
phospholipid-binding proteins targeted are
β-2-glycoprotein-I (β2GPI) and prothrom-
bin.4-6 They have higher affinities for anionic
phospholipids upon binding with certain
aPL7-9 and therefore may interfere with phos-
pholipid-dependent coagulation reactions
and contribute to the prothrombotic state.
The major pathway of blood coagulation,
the tissue factor (TF) pathway, is triggered
by TF in complex with activated coagulation
factor VII (FVIIa). Tissue factor pathway
inhibitor (TFPI) is a natural anticoagulant
that regulates TF: FVIIa proteolytic activity
against coagulation factors X (FX) and IX
(FIX), by either binding to activated FX
(FXa), then to TF: FVIIa, or forming a com-
plex directly with TF: FVIIa: FXa.10,11 The
resulting quaternary TF: FVIIa: FXa: TFPI
complex prevents further TF: FVIIa activity
and consequentially decreases thrombin
generation and fibrin formation. There is
increasing evidence that antibodies with
activity against TFPI have a significant role
in the development of an increased throm-
botic tendency observed in aPS patients.12-17
High titers of anti-TFPI autoantibodies have
recently been detected with greater frequen-
cy among aPS patients compared to patients
with aPL only and healthy controls.12
Furthermore, an inhibitory component to
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Background and Objectives. Recent evidence suggests that autoantibodies to tissue
factor pathway inhibitor (TFPI) and/or antiphospholipid antibodies (aPL) may contribute
to upregulation of the tissue factor (TF) pathway of blood coagulation and the develop-
ment of thrombotic complications in the antiphospholipid syndrome (aPS). The aim of
this study was to determine the influence of aPL e.g. anti-β-2-glycoprotein-I (anti-β2GPI)
and anti-prothrombin, on in vitro TF-induced thrombin generation in the presence and
absence of TFPI.
Design and Methods. IgG fractions were collected from subjects with aPL (n=21) and
normal controls (n=36). Anti-TFPI activity was determined after incubation of IgG isolat-
ed from control or subject plasma with pooled normal plasma using an amidolytic
assay for TFPI.  The influence of IgG fractions and purified aPL (anti-β2GPI and anti-pro-
thrombin) on TF-induced in vitro thrombin generation was determined using a chro-
mogenic assay of thrombin activity.
Results. Patients with aPL had significantly elevated thrombin generation (median
[interquartile range]) compared to normal controls (112.0 [104.0-124.0]% vs 89.9
[85.7-100.9]%, respectively; p<0.001). Thrombin generation was significantly correlat-
ed with anti-TFPI activity in patients with aPL (rs=0.452; p=0.039). It was also demon-
strated that anti-β2GPI, but not anti-prothrombin IgG antibodies, significantly enhanced
TF-induced thrombin generation in the presence of TFPI, using both purified and
patients’ samples.
Interpretation and Conclusions. Our findings support the hypothesis that anti-β2GPI IgG
antibodies accelerate thrombin generation in the presence of TFPI and may contribute
to hypercoagulability in patients with aPS.
Key words: antiphospholipid antibodies, tissue factor pathway inhibitor, thrombin
generation, β-2-glycoprotein-I.
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TFPI has been identified in the IgG fraction of aPS
patients,13 which is associated with increased in vitro TF-
induced thrombin generation.14 It is probable that this
inhibitory component is an anti-TFPI antibody and/or
another aPL with inhibitory activity against TFPI. Thus,
inhibitors of TFPI or interference to TFPI activity, cou-
pled with an aPL-induced increase in TF-like activity
from monocytes and endothelial cells,18,19 may upregu-
late the TF pathway and contribute to hypercoagulabil-
ity in aPS.
The aim of this study was to determine the influence
of markers of aPS e.g. anti-β2GPI and anti-prothrombin
antibodies, on in vitro TF-induced thrombin generation.
It was hypothesised that aPL would interfere with the




This study was approved by the Human Research
Ethics Committee of Curtin University of Technology
(Approval Number: HR 238/2001).
Patients and controls
Plasma from 21 patients with aPL (mean age=57.4
years; age range=30-79 years) was collected from
Fremantle Hospital (Fremantle, Australia) and Royal
Perth Hospital (Perth, Australia). Plasma samples were
aliquoted and stored at -80°C until assay.  Normal con-
trol plasma was collected from 36 volunteers (mean
age=29.3 years; age range=19-60 years) with no appar-
ent hemostatic abnormality from the School of
Biomedical Sciences (Curtin University of Technology,
Perth, Australia).  Nine parts of venous blood was col-
lected in one part of 0.109 M tri-sodium citrate antico-
agulant and centrifuged for 15 minutes at 3000 g.
Plasma was collected and centrifuged again for 15 min-
utes at 3000 g to obtain platelet poor plasma. Equal vol-
umes of platelet-poor plasma from 20 healthy male
donors were pooled to prepare normal pooled plasma
(NPP).
Plasmas, proteins and antibodies
NPP was used as the reference control in the anti-TFPI
activity and TF-induced thrombin generation assays.
TFPI-depleted plasma (TDP) and recombinant human
TFPI (rTFPI) were purchased from American
Diagnostica Inc. (Stamford, CT, USA).  Purified human
prothrombin, purified human β2GPI, affinity purified
polyclonal rabbit anti-human β2GPI antibodies and
affinity purified polyclonal rabbit anti-human pro-
thrombin antibodies were purchased from Hyphen
Biomed (Neuville, France). Polyclonal sheep anti-human
TFPI IgG antibody was purchased from Hematologic
Technologies Inc. (Essex Junction, VT, USA).  Rabbit
anti-sheep IgG (Silenus, Hawthorn, Australia), sheep
anti-rabbit IgG (Silenus, Hawthorn, Australia) and affin-
ity purifed goat anti-human IgG, IgA, IgM and light
chain (Biosource International, Camarillo, USA) were
alkaline phosphatase-conjugated antibodies used in
immunoblotting.
IgG isolation
IgG was isolated from plasma using a HiTrapTM
Protein G 1mL column (Amersham Pharmacia Biotech,
Uppsala, Sweden) according to the manufacturer’s
instructions and as described previously.14 Isolated IgG
(2.5 mL) was buffer exchanged into 3.5mL of 0.9%
NaCl or TFPI assay buffer pH 8.0 (0.05mol/L tris,
0.15mol/L NaCl, 0.01M tri-sodium citrate, 0.2g/L poly-
brene and 0.1% normal serum albumin) using a PD 10
desalting column (Amersham Pharmacia Biotech,
Uppsala, Sweden) equilibrated with 25 mL of PBS.  The
concentration of IgG was calculated by dividing the IgG
eluate absorbance by an extinction coefficient of 1.43
and multiplying by the total volume (3.5mL). Aliquots
of IgG were stored at -80°C.
TF-induced thrombin generation assay
In vitro thrombin generation in plasma was measured
using a chromogenic assay20 recently modified by our
laboratory.14 Prior to assay, platelet-poor plasma was
heated for 15 minutes at 49° C, cooled on melting ice for
2 minutes and centrifuged for 15 minutes at 3000 g to
remove fibrinogen. Defibrinated plasma diluted 1/2 in
0.9% NaCl, or protein (50 µL/well) was incubated with
IgG or antibody (25 µL/well) for 20 minutes at room
temperature in the well of a 96-well round bottomed
microtiter plate. Thromboplastin (Innovin®, Dade
Behring, Marburg, Germany) diluted 1/20 in 0.9% NaCl
was added (25 µL/well) and the mixture incubated for
10 minutes at 37°C. A chromogenic substrate specific
for thrombin (Biophen CS-0138 Thrombin Chromogenic
Substrate, Hyphen Biomed, Neuville, France), diluted to
1 mmol/L in 0.9% NaCl was then added (50 µL/well)
followed by 30 mmol/L CaCl2 (50 µL/well). The final
reaction volume was 200 µL. Using a Multiskan Ascent
microtiter plate spectrophotometer the plate was read
at 405nm immediately and every two minutes until
peak absorbance was reached.  Background absorbance
was accounted for each sample by substituting throm-
bin chromogenic substrate with 0.9% NaCl.
The rate of thrombin generation in a test sample was
expressed as a percentage of the absorbance reached by
the test sample compared to the reference control (con-
taining NPP only) when the reference control reached
half maximum absorbance. Thrombin generation in
NPP was designated at 100%.
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Anti-TFPI activity
Anti-TFPI activity was determined as previously
described.14 Equal volumes of NPP and 25 µg/mL IgG or
antibody were incubated for 30 minutes at 37°C and then
assayed in the TFPI activity assay.21 Anti-TFPI activity was
the difference of TFPI activity between the IgG/NPP mix-
ture and the 1U/mL control (buffer/NPP).
Immunoblotting
Immunoblotting (dot blot) involved immobilization of
proteins on to a synthetic membrane support and recogni-
tion of the proteins’ native epitopes by test antibodies. A
polyvinylidene fluoride (PVDF) membrane (Hybond™-P,
Amersham Biosciences, Buckinghamshire, UK) was pre-
pared by immersion in 100% methanol and then tris-
buffered saline (TBS) pH 8.0. Antigens (TFPI, β2GPI and
prothrombin) (5 µg/mL) were blotted (0.5 µL per dot) onto
the PVDF membrane and allowed to dry. Blocking solu-
tion (5% skim milk in TBS buffer containing 0.05%
Tween pH 8.0) was added and incubated with gentle agi-
tation at room temperature for 30 minutes. The mem-
brane was sequentially incubated with gentle agitation for
1 hour at room temperature or overnight at 4°C, in pri-
mary antibody (0.5-10 µg/mL antibody in blocking solu-
tion) and washed three times in TBS buffer containing
0.05% Tween pH 8.0 at 10-minute intervals. Secondary
antibody (0.5 µg/mL alkaline phosphatase-conjugated
antibody in blocking solution) was added and incubated
with gentle agitation for 1 hour at room temperature or
overnight at 4°C, followed by three washes in TBS buffer
containing 0.05% Tween pH 8.0 at 10-minute intervals.
Color development was generated using an alkaline phos-
phatase-conjugate chromogenic substrate (Biorad,
California, USA). Deionized water stopped the reaction
and the membrane was dried at 37°C.
Statistical analysis
All experiments were performed in duplicate.  Statistical
analysis was performed using Superior Performance
Statistical Software® (SPSS) for Mac® OS X (version
11.0.2.). Results for the effect of IgG on thrombin genera-
tion were expressed as the median (interquartile range) as
data was not normally distributed. Wilcoxon’s signed rank
test was used to test for the differences between groups.
Correlation between the effect of IgG on thrombin gener-
ation and anti-TFPI activity was derived using Spearman’s
rank correlation test (rs). All other results are reported as
mean±standard deviation. Statistical significance was
defined at p values of <0.05.
Results
Thrombin generation and anti-TFPI activity
Sheep anti-human TFPI antibody induced a dose-
dependent increase in thrombin generation and normal
control IgG had no significant effect on thrombin gener-
ation (Figure 1). The effect of IgG on thrombin genera-
tion was significantly greater in patients [112.0 (104.0-
124.0)%] than in controls [89.9 (85.7–100.9)%;
p<0.001]. Anti-TFPI activity was confirmed in 10/21
(47.6 %) of patients and was significantly correlated
with the effect of IgG on thrombin generation
(rs=0.452; p=0.039) (Figure 2). This relationship was
reproducible on two separate occasions.
Interaction of purified protein and antibody markers
Thrombin generation in NPP (100%) was individual-
ly reduced by rTFPI (73.1±3.8%), anti-β2GPI antibodies
(74.9±10.1%) and anti-prothrombin antibodies
(22.7±1.7%) (Figure 3). In the presence of additional
TFPI, thrombin generation in NPP was increased by
anti-β2GPI (110.0±2.1%) and decreased by anti-pro-
thrombin (17.3±1.2%) (Figure 3). These results were
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Figure 1. Effect of sheep anti-human TFPI control antibody (P)
and normal control IgG (p) on thrombin generation in NPP. Anti-
human TFPI antibody induced a dose-dependent increase in
thrombin generation and normal control IgG had no significant
effect on thrombin generation.
Figure 2.  Thrombin generation and anti-TFPI activity in IgG frac-
tions of patients with aPL.  The effect of patients’ IgG on thrombin
generation was significantly correlated with anti-TFPI activity
(rs=0.452; p=0.039).
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reproducible and enhanced in TDP. Compared to NPP,
TDP had higher thrombin generation (139.9±13.5%),
which was reduced with TFPI (55.3±10.6%), anti-β2GPI
(34.9±6.0%) and anti-prothrombin (21.3±0.9%) (Figure
4). Thrombin generation in TDP spiked with TFPI was
markedly increased by anti-β2GPI (198.0±18.5%) and
decreased by anti-prothrombin (18.5±0.2%) (Figure 4). 
Purified antibodies (anti-TFPI, anti-β2GPI and anti-
prothrombin) demonstrated specificity for their target
antigen with no cross-reactivity (Figure 5).
Interaction of patient IgG with purified protein and
antibody markers
IgG fractions from ten patients with aPL were divided
into two groups (five patients with and five without
anti-TFPI activity) and assessed for their effect on
thrombin generation in TDP, in the presence and
absence of TFPI. Thrombin generation in TDP was sim-
ilarly decreased with IgG from patients with anti-TFPI
activity (85.7±11.4%) and without anti-TFPI activity
(85.9±19.9%) (Figure 6). Thrombin generation in TDP
spiked with TFPI was significantly increased by IgG
from patients with anti-TFPI activity (135.8±33.7%)
compared to IgG from patients without anti-TFPI activ-
ity (83.3±25.0%) (p=0.005) (Figure 6).
Discussion
Despite its discovery more than two decades ago,22
aPS remains an enigma. Laboratory diagnosis and treat-
ment of aPS is often difficult due to limited understand-
ing of its pathophysiology. To date, no single pathogen-
ic mechanism sufficiently explains how aPL contribute
Anti-β2GPI and TFPI accelerate thrombin generation
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Figure 3. Effect of anti-β2GPI (100 µg/mL) and anti-prothrombin
(100 µg/mL) antibodies on thrombin generation in NPP in the
presence and absence of rTFPI (100 ng/mL). Thrombin generation
was enhanced by anti-β2GPI, but not anti-prothrombin, in NPP
spiked with rTFPI. 1: NPP; 2: TDP; 3: NPP+TFPI; 4: NPP+anti-
β2GPI; 5: NPP+anti-β2GPI+TFPI; 6: NPP+anti-prothrombin; 7:
NPP+anti-prothrombin + TFPI.
Figure 4. Effect of anti-β2GPI (100 µg/mL) and anti-prothrombin
(100 µg/mL) antibodies on thrombin generation in TDP in the
presence and absence of rTFPI (100 ng/mL).  Thrombin genera-
tion was enhanced by anti-β2GPI, but not anti-prothrombin, in the
presence of rTFPI in TDP. 1: NPP; 2: TDP; 3: TDP+TFPI; 4:
TDP+anti-β2GPI; 5: TDP+anti-β2GPI+TFPI; 6: TDP+anti-prothrom-
bin; 7: TDP+anti-prothrombin+TFPI.
Figure 5.  Antigen specificity of purified anti-
bodies by immunoblotting.  No cross-reactivity
was demonstrated between antigens and anti-
bodies.  Arrows indicate positive reactions. TBS
pH 8.0 was a negative control.










































to the development of thrombosis in aPS and account
for all clinical manifestations observed in patients. It
may be that an array of pathogenic mechanisms con-
tributes to an ongoing hypercoagulable state. Recently,
interference to the control of the TF pathway of blood
coagulation has been implicated in the pathogenesis of
thrombotic aPS.12-17,23,24 Therefore, the aim of the present
study was to determine the influence of anti-β2GPI and
anti-prothrombin aPL on the TF pathway in the pres-
ence and absence of TFPI. It was clearly demonstrated
that anti-β2GPI, but not anti-prothrombin IgG antibod-
ies interfere with TFPI-dependent inhibition of TF-
induced thrombin generation.
Anti-β2GPI antibodies, anti-prothrombin antibodies
and rTFPI reduced thrombin generation in both NPP
(Figure 3) and TDP (Figure 4). TFPI is a natural anticoag-
ulant and inhibits thrombin generation through its
inhibitory activity against FXa and the TF: FVIIa com-
plex. In contrast, anti-β2GPI and anti-prothrombin are
acquired antibodies with an anticoagulant effect on in
vitro TF-induced thrombin generation.20,25 Their antico-
agulant activities may be mediated by binding with
their co-factors as it has been demonstrated that the
anti-β2GPI: β2GPI complex7,9,26 and anti-prothrombin:
prothrombin complex8,27 have increased affinities for
anionic phospholipids and thereby may compete with
other coagulation factors for the binding to anionic
phospholipids. Thus, in vitro thrombin generation may
be inhibited by anti-β2GPI and anti-prothrombin anti-
bodies due to decreased catalytic phospholipid surfaces
for assembly and activation of coagulation factors.
Despite the demonstrated reduction of in vitro thrombin
generation, anti-β2GPI and anti-prothrombin antibodies
are associated with thrombotic complications in aPS.
The reason for this paradox is presently unclear.
Thrombin generation in both NPP and TDP spiked
with rTFPI was increased by anti-β2GPI antibodies and
decreased by anti-prothrombin antibodies (Figures 3
and 4). This suggests that anti-β2GPI, but not anti-pro-
thrombin antibodies have inhibitory activity towards
TFPI. Anti-β2GPI anti-TFPI-like activity has been previ-
ously reported.16 Using a FXa generation assay initiated
with low concentrations of recombinant TF (rTF), phos-
phatidylserine (anionic phospholipids) and phos-
phatidylcholine (neutral phospholipids), it was demon-
strated that anti-β2GPI IgG antibodies isolated from aPS
patients required TFPI and β2GPI to enhance FXa gener-
ation. The authors of this study subsequently hypothe-
sized that the anti-β2GPI: β2GPI complex interfered with
TFPI dependent inhibition of FXa by competing with
the TFPI: FXa complex for the same phospholipid bind-
ing sites to therefore increase FXa generation.  Although
this hypothesis was not tested, it could have been sup-
ported if the stimulatory effect of anti-β2GPI IgG anti-
bodies on FXa generation was neutralized in presence of
high concentrations of phospholipids. In the present
study, the stimulatory effect of anti-β2GPI and TFPI was
demonstrated by increased thrombin generation with
the reaction initiated by high concentrations of throm-
boplastin (rTF and synthetic phospholipids). Therefore,
the mechanism by which anti-β2GPI inhibits TFPI activ-
ity is probably not related to the competition of proteins
for binding to catalytic phospholipid surfaces. Instead,
the current study proposes a novel mechanism whereby
anti-β2GPI binds directly or indirectly to TFPI. This
binding may then completely or partially abolish TFPI-
dependent inhibition of blood coagulation resulting in
accelerated thrombin generation.
Immunoblotting was used to determine whether anti-
β2GPI IgG antibody binds directly to TFPI. The interac-
tion between aPL and their target proteins is currently
not well understood, with two models of interaction
proposed in the literature. The first model proposed that
aPL may recognize and bind epitopes on the conforma-
tionally altered protein structure resulting from interac-
tions with an oxidized surface or anionic phospho-
lipids.28 The other model describes aPL as low-affinity
antibodies that require their target antigen in high den-
sities to form divalent complexes.26,29 No cross-reactivity
was demonstrated between anti-β2GPI IgG and TFPI
(Figure 5). Other possible mechanisms may include anti-
β2GPI antibody binding a neo-epitope on TFPI when
bound to FXa or the anti-β2GPI: β2GPI complex blocking
TFPI binding to FXa.
Anti-β2GPI in the presence of TFPI has inhibitory
activity against the regulation of TF-induced blood
coagulation. Additions of anti-β2GPI and TFPI in TDP
resulted in elevated thrombin generation, compared to
TDP alone (Figure 4). This inhibitory component may
be another natural anticoagulant e.g. protein C,
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Figure 6. Mean effect of IgG (25 µg/mL) from patients with (n=5)
and without (n=5) anti-TFPI activity on thrombin generation in TDP,
in the presence and absence of rTFPI (50 ng/mL). Mean thrombin
generation was significantly enhanced by IgG from patients with
anti-TFPI activity, but not with IgG from patients without anti-TFPI
activity, in the presence of rTFPI, in TDP (p=0.005). 1: NPP; 2: TDP;
3: TDP+TFPI; 4: TDP+patient IgGs with anti-TFPI activity; 5:
TDP+patient IgGs with anti-TFPI activity+TFPI; 6: TDP+patient IgGs
without anti-TFPI activity; 7: TDP+patient IgGs without anti-TFPI
activity TFPI.



















antithrombin, or β2GPI. Although the physiological role
of β2GPI has not been established, it has been reported
to have procoagulant and anticoagulant effects in blood
coagulation.30 In keeping with the mechanisms suggest-
ed earlier between anti-β2GPI and TFPI, it is possible
that this inhibitory component is β2GPI. Anti-β2GPI may
preferentially bind to TFPI in the presence of increased
concentrations of TFPI compared to β2GPI, thus simul-
taneously inhibiting the anticoagulant functions of TFPI
and β2GPI, resulting in enhanced thrombin generation.
Thrombin generation in TDP was reduced in groups
of patients with and without anti-TFPI activity (Figure
6), reflecting anticoagulant activities of anti-β2GPI and
anti-prothrombin IgG antibodies. In comparison,
thrombin generation in TDP spiked with TFPI was sig-
nificantly enhanced by IgG fractions from the group
with anti-TFPI activity and essentially unchanged by
the group without anti-TFPI activity (Figure 6). These
findings demonstrate that the entity in IgG fractions
from patients with aPL responsible for the increase in
thrombin generation compared to IgG fractions from
normal controls, has anti-TFPI activity.  It is probable
that this entity is an anti-TFPI IgG and/or anti-β2GPI IgG
antibody. Isolation of these entities from IgG fractions
will help elucidate the antibodies involved.
This study represents the first work to provide evi-
dence that anti-TFPI-like activity expressed by both
anti-TFPI and anti-β2GPI IgG antibodies is associated
with increased in vitro TF-induced thrombin generation.
The precise relationship and/or interactions between
anti-β2GPI antibodies, TFPI and potentially other as yet
unidentified entities, remains to be determined. The
findings from this study will provide better understand-
ing of how interactions within the TF pathway may
contribute to thrombotic complications in aPS.
Additionally, these results may have implications for
the use of rTFPI as an antithrombotic agent in patients
with aPL.
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